These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1025 related articles for article (PubMed ID: 18830124)

  • 21. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol.
    Powell CB; Chen LM; McLennan J; Crawford B; Zaloudek C; Rabban JT; Moore DH; Ziegler J
    Int J Gynecol Cancer; 2011 Jul; 21(5):846-51. PubMed ID: 21670699
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.
    Lee YJ; Lee SW; Kim KR; Jung KH; Lee JW; Kim YM
    J Gynecol Oncol; 2017 Jan; 28(1):e3. PubMed ID: 27670257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy.
    Eitan R; Soslow R; Lin O; Kauff ND; Liu L; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Aug; 102(2):315-8. PubMed ID: 16430946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation.
    Rabban JT; Mackey A; Powell CB; Crawford B; Zaloudek CJ; Chen LM
    Gynecol Oncol; 2011 Jun; 121(3):466-71. PubMed ID: 21353295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers.
    Vicus D; Shaw PA; Finch A; Rosen B; Murphy J; Armel S; Sun P; Narod SA
    Gynecol Oncol; 2010 Sep; 118(3):295-8. PubMed ID: 20722102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Rush SK; Swisher EM; Garcia RL; Pennington KP; Agnew KJ; Kilgore MR; Norquist BM
    Gynecol Oncol; 2020 May; 157(2):514-520. PubMed ID: 32199636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis.
    Paley PJ; Swisher EM; Garcia RL; Agoff SN; Greer BE; Peters KL; Goff BA
    Gynecol Oncol; 2001 Feb; 80(2):176-80. PubMed ID: 11161856
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
    Kindelberger DW; Lee Y; Miron A; Hirsch MS; Feltmate C; Medeiros F; Callahan MJ; Garner EO; Gordon RW; Birch C; Berkowitz RS; Muto MG; Crum CP
    Am J Surg Pathol; 2007 Feb; 31(2):161-9. PubMed ID: 17255760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nongynecologic metastases to fallopian tube mucosa: a potential mimic of tubal high-grade serous carcinoma and benign tubal mucinous metaplasia or nonmucinous hyperplasia.
    Rabban JT; Vohra P; Zaloudek CJ
    Am J Surg Pathol; 2015 Jan; 39(1):35-51. PubMed ID: 25025442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
    J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A; Shaw P; Rosen B; Murphy J; Narod SA; Colgan TJ
    Gynecol Oncol; 2006 Jan; 100(1):58-64. PubMed ID: 16137750
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Routine Peritoneal and Omental Biopsies at Risk-Reducing Salpingo-Oophorectomy.
    Miller H; Pipkin LS; Tung C; Hall TR; Masand RP; Anderson ML
    J Minim Invasive Gynecol; 2017; 24(5):772-776. PubMed ID: 28285055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.
    Callahan MJ; Crum CP; Medeiros F; Kindelberger DW; Elvin JA; Garber JE; Feltmate CM; Berkowitz RS; Muto MG
    J Clin Oncol; 2007 Sep; 25(25):3985-90. PubMed ID: 17761984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy.
    McEwen AR; McConnell DT; Kenwright DN; Gaskell DJ; Cherry A; Kidd AM
    Gynecol Oncol; 2004 Mar; 92(3):992-4. PubMed ID: 14984974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rhiem K; Foth D; Wappenschmidt B; Gevensleben H; Büttner R; Ulrich U; Schmutzler RK
    Arch Gynecol Obstet; 2011 Mar; 283(3):623-7. PubMed ID: 20428881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
    Morrison JC; Blanco LZ; Vang R; Ronnett BM
    Am J Surg Pathol; 2015 Apr; 39(4):442-53. PubMed ID: 25517955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.